Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/108575

Título:	Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?
Autor/a:	Ampudia-Blasco, Francisco Javier; Romera, Irene; Ariño, Bernat; Gomis, Ramon, 1946-
Otros autores:	Universitat de Barcelona
Abstract:	The recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors.
Materia(s):	-Malalties cardiovasculars -Diabetis -Glucosa -Cardiovascular diseases -Diabetes -Glucose
Derechos:	cc-by-nc (c) Ampudia-Blasco, Francisco Javier, 2017 http://creativecommons.org/licenses/by-nc/3.0/es/
Tipo de documento:	Artículo Artículo - Versión publicada
Compartir:

Mostrar el registro completo del ítem